About Neuro-bio limited
Neuro-Bio Limited: Pioneering the Fight Against Alzheimer's Disease
Neuro-Bio Limited is a privately-owned biotech company that has been making waves in the field of Alzheimer's disease research. Based out of Oxford University, Neuro-Bio is dedicated to discovering oral drugs that can effectively treat this debilitating condition.
Alzheimer's disease is a progressive brain disorder that affects millions of people worldwide. It causes memory loss, cognitive decline, and eventually leads to death. Despite decades of research, there are currently no effective treatments for this devastating condition.
This is where Neuro-Bio comes in. The company was founded by Dr. John Davis and Professor Zameel Cader in 2013 with the goal of developing new therapies for Alzheimer's disease. They recognized that traditional drug discovery methods were not working and decided to take a different approach.
Neuro-Bio uses a unique platform technology called "Network Resetting Technology" (NRT) to identify potential drug candidates for Alzheimer's disease treatment. NRT works by analyzing the complex network interactions within brain cells and identifying key targets for drug intervention.
The company has already made significant progress in its mission to develop effective treatments for Alzheimer's disease. In 2018, they announced positive results from preclinical studies on their lead compound NB01, which showed promising effects on reducing amyloid beta levels - one of the hallmarks of Alzheimer's disease pathology.
In addition to its work on NB01, Neuro-Bio has several other compounds in development targeting different aspects of Alzheimer's pathology such as neuroinflammation and tau protein aggregation.
One thing that sets Neuro-Bio apart from other biotech companies is its commitment to transparency and collaboration with academic institutions and other industry partners. The company actively seeks out partnerships with leading researchers in the field to advance their understanding of Alzheimer’s biology and accelerate drug discovery efforts.
Another unique aspect of Neuro-Bio’s approach is its focus on developing oral drugs. Most current treatments for Alzheimer's disease are administered via injection or infusion, which can be inconvenient and uncomfortable for patients. Neuro-Bio’s oral drug candidates have the potential to be more patient-friendly and accessible.
Neuro-Bio is also committed to sustainability and ethical practices in its drug development efforts. The company has implemented a "green chemistry" approach to minimize environmental impact and reduce waste in its manufacturing processes.
Overall, Neuro-Bio Limited is a promising biotech company that is making significant strides in the fight against Alzheimer's disease. With its innovative technology platform, commitment to collaboration, and focus on patient-friendly treatments, Neuro-Bio has the potential to revolutionize the field of Alzheimer's research and bring hope to millions of people affected by this devastating condition.